Significance of hepatic resection combined with inferior vena cava resection and its reconstruction with expanded polytetrafluoroethylene for treatment of liver tumors.
BACKGROUND
Resection of the IVC is required when a liver tumor invading the IVC is completely removed. The purpose of this study was to evaluate the clinical significance of hepatectomy combined with IVC resection and reconstruction with an ePTFE graft for treatment of invasive liver tumors and to discuss the validity of this surgery.


METHODS
Eleven selected patients with liver tumors underwent various types of hepatectomy with retrohepatic IVC resection, followed by IVC reconstruction. The postoperative courses, clinicopathologic features of the tumors, operative procedures, and outcomes of the patients were studied.


RESULTS
Ten of 11 patients did not require an active ventriculovenous bypass using a biopump. Invasion to the IVC was histologically proved in 9 of the 11 patients. After reconstruction, all artificial vessel grafts maintained patency throughout the observation period. Four patients are still alive with cancer-free status ranging from approximately 11 years to 5 months. One-year, 3-year, and 5-year survival rates were 63.6%, 38.2%, and 25.5%, respectively, with a 50% survival of 29 months.


CONCLUSIONS
IVC resection and its reconstruction with ePTFE for treatment of liver tumors was safely performed on 11 selected patients with a 50% survival of 29 months. Patency of the graft was maintained for the longterm without infectious complications. This surgical procedure is indicated in some select patients in whom IVC invasion is extensive.
Arii
Shigeki
S
Department of Surgery, Tokyo Medical and Dental University, Tokyo, Japan.
Teramoto
Kennichi
K
Kawamura
Toru
T
Takamatsu
Susumu
S
Sato
Eigo
E
Nakamura
Noriaki
N
Iwai
Takahisa
T
Mori
Akira
A
Tanaka
Junji
J
Imamura
Masayaki
M
D000310:Adrenal Gland Neoplasms / Q000473:pathology; D000328:Adult; D000368:Aged; D019917:Blood Vessel Prosthesis Implantation / Q000379:methods*; D006528:Carcinoma, Hepatocellular / Q000473:pathology / Q000601:surgery*; D018281:Cholangiocarcinoma / Q000473:pathology / Q000601:surgery*; D005260:Female; D006498:Hepatectomy / Q000379:methods*; D006801:Humans; D007890:Leiomyosarcoma / Q000473:pathology; D008113:Liver Neoplasms / Q000473:pathology / Q000556:secondary / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D011138:Polytetrafluoroethylene / Q000627:therapeutic use; D012186:Retroperitoneal Neoplasms / Q000473:pathology; D016019:Survival Analysis; D016896:Treatment Outcome; D019043:Vascular Neoplasms / Q000601:surgery*; D014682:Vena Cava, Inferior / Q000473:pathology / Q000601:surgery*
D011138:Polytetrafluoroethylene